Jan 20 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS
Source text: ID:nBw858hTTa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Jan 20 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA'S LP-284 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SOFT TISSUE SARCOMAS
Source text: ID:nBw858hTTa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Comments